The acquisition of Lemonaid signals the company is now on its way toward becoming involved in every step of a patient's care, from assessing their health risks to developing drugs.
(Bloomberg) –Consumer DNA testing giant 23andMe Holding Co. agreed to purchase telehealth upstart and drug-delivery service Lemonaid Health Inc. in a bid to make its personalized genetics approach part of patients' primary care.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
